ArticleBMC oral health2026
Metformin modulates alveolar bone parameters and gene expression in streptozotocin-induced type 2 diabetic rats.
Article in BMC oral health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDiabetes mellitus (DM) is linked with defective bone healing and metabolic disturbances that increase fracture risk. Although metformin (MET) is used traditionally as first-line treatment for type 2 diabetes (T2DM), its effectiveness in completely reversing diabetic bone homeostasis is uncertain. The present study was conducted to assess the short-term effect of MET on alveolar bone histological structure and osteoblastic gene expression in rats with streptozotocin (STZ)-induced type 2 diabetes mellitus (T2DM).
methodsEighteen adult male Wistar rats were divided equally into three groups (n = 6/group): control group (non-diabetic) was injected with saline, STZ group (diabetic) received 10% fructose solution for 2 weeks followed by an injection of a single dose of STZ (40 mg/kg), and MET group (diabetic with MET-treatment) received 100 mg/kg/day MET for 30 days. Alveolar bone was assessed by histological and histomorphometric analysis, cone beam computed tomography (CBCT), and reverse transcription-polymerase chain reaction (RT-PCR) analysis of bone-related gene expression.
resultsThe STZ group showed pronounced decreases in total bone area, osteoblast area, and bone-related gene expression (RunX2, osteocalcin, COL1A1) compared to the control group. MET significantly improved these parameters compared to the STZ group.
conclusionsMetformin significantly increased total bone area and osteoblastic gene expression (Runx2, osteocalcin, and COL1A1) compared to untreated diabetic rats but did not fully restore them to control (non-diabetic) levels. These results suggest a partial protective effect of metformin in alveolar bone in this short-term T2DM rat model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.